RecruitingPhase 1/2

Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

United States20 participantsStarted 2021-08-01

Plain-language summary

Patients will receive one of two conditioning regimens (BEAM or CBV) before receiving an autologous stem cell transplant (ASCT). If patients achieve either complete, partial, or stable response following ASCT, they will receive an IV dose of Polatuzumab Vedotin once every 21 days until they receive 8 doses. After Polatuzumab Vedotin therapy is completed, patients will be followed every 4 months for about 2 years.

Who can participate

Age range12 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Myelosuppressive chemotherapy: Must not have received within 2 weeks of entry onto this study (4 weeks if prior nitrosourea).
✓. Biologic (anti-neoplastic agent): At least 7 days since the completion of therapy with a biologic agent.

What they're measuring

Safety and tolerability

Timeframe: 1 year

Trial details

NCT IDNCT04491370

SponsorNew York Medical College

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-08-15

Contact for this trial

Lauren Harrison, RN

6172857844 lauren_harrison@nymc.edu

View on ClinicalTrials.gov More B-cell Lymphoma trials